Market Access Fighting fake GLP-1s to protect patients & preserve trust Counterfeit drug promotion is a patient safety, brand equity, and public trust issue.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Patients Using patient data to fill in GLP-1 blind spots, with Phil J... At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
R&D Beyond GLP-1: Preclinical hurdles and solutions for next-gen... The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.
News Novo rapped by FDA for not reporting drug adverse effects Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
